| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Net revenue | 8,095 | 6,964 | 6,500 | |
| Cost of revenue | 2,659 | 2,298 | 2,093 | |
| Gross profit | 5,436 | 4,666 | 4,407 | |
| General and administrative | 5,900 | 6,162 | 6,262 | |
| Research and development | 1,784 | 1,886 | 1,853 | |
| Impairment expense | - | - | 55,833 | |
| Selling and marketing | 4,358 | 4,653 | 5,007 | |
| Loss from operations | -6,606 | -8,035 | -64,548 | |
| Interest income | 561 | 629 | 730 | |
| Loss on disposal of assets | -36 | 1 | -8 | |
| Other (expense) income | -13 | -39 | -44 | |
| Foreign exchange (loss) gain | -46 | 58 | 4 | |
| Loss before income taxes | -6,140 | -7,386 | -63,866 | |
| Income tax benefit | -19 | 12 | -57 | |
| Net loss | -6,121 | -7,398 | -63,809 | |
| Unrealized gain, change in fair value of available-for-sale securities, net of tax | 34 | -10 | -18 | |
| Change in foreign currency translation | -18 | 55 | 62 | |
| Net loss and comprehensive loss | -6,105 | -7,353 | -63,765 | |
| Earnings per share, basic | -0.01 | -0.01 | -0.07 | |
| Earnings per share, diluted | -0.01 | -0.01 | -0.07 | |
| Weighted average number of shares outstanding, basic | 979,949,668 | 979,949,668 | 979,949,668 | |
| Weighted average number of shares outstanding, diluted | 979,949,668 | 979,949,668 | 979,949,668 | |
Zomedica Corp. (ZOMDF)
Zomedica Corp. (ZOMDF)